Search - tctmd.com

Displaying 1 - 20 of 58

Sort: Relevancy | Date

News Daily News

Public Reporting Tied to Better Care, but Similar Outcomes, in Stroke Centers

Todd Neale

January 16, 2026

News Daily News

Patient Age Adds Key Context to D-Dimer in DVT Diagnosis: ADJUST-DVT

Caitlin E. Cox

January 08, 2026

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Caitlin E. Cox

September 01, 2025

Presentation ACC 2025

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Presenter: Isabelle Mahé

March 29, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

Presentation TCT 2024

Where Does Interventional Cardiologist Fit in Advancing Interventional Treatment of Pulmonary Thromboembolism?

Presenter: Riyaz Bashir

October 28, 2024

News Daily News

Different Guidelines for Acute PE Offer a Mixed Bag of Advice

Caitlin E. Cox

October 08, 2024

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

L.A. McKeown

August 26, 2024

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

L.A. McKeown

August 19, 2024

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

News Daily News

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

Shelley Wood

January 17, 2024

Presentation TCT 2023

TCT 624: Patient-Reported Outcomes in Venous Thromboembolism: Current Status and Future Directions

Presenter: Daniel Snyder

October 24, 2023

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

L.A. McKeown

August 30, 2023

News Conference News SCAI 2023

FLASH: PE Patients Show Ongoing Clinical, QoL Gains With Thrombectomy

L.A. McKeown

May 21, 2023

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Presentation TCT 2022

Latest innovations in Thrombectomy for Venous Thromboembolism

Presenter: Lawrence Garcia

September 18, 2022

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

L.A. McKeown

June 29, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

Michael O'Riordan

November 29, 2021

Advertisement

Public Reporting Tied to Better Care, but Similar Outcomes, in Stroke Centers

Patient Age Adds Key Context to D-Dimer in DVT Diagnosis: ADJUST-DVT

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

What’s Going to Be Hot at ACC 2025?

Where Does Interventional Cardiologist Fit in Advancing Interventional Treatment of Pulmonary Thromboembolism?

Different Guidelines for Acute PE Offer a Mixed Bag of Advice

Scientific Statement Reviews Current Antithrombotic Options in PAD

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

TCT 624: Patient-Reported Outcomes in Venous Thromboembolism: Current Status and Future Directions

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

FLASH: PE Patients Show Ongoing Clinical, QoL Gains With Thrombectomy

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Latest innovations in Thrombectomy for Venous Thromboembolism

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content